A phase III trial failed to demonstrate superiority of eribulin over treatment of physician’s choice (TPC) in patients with heavily pretreated non–small-cell lung cancer (NSCLC). The agent did have activity in this setting, but did not improve outcomes over other options.
“Despite the availability of second-line therapies, including pemetrexed, erlotinib, and docetaxel, clinical evidence of third-line or later treatment options still remains limited,” wrote study authors led by Nobuyuki Katakami, MD, PhD, of the Institute of Biomedical Research and Innovation Hospital in Kobe, Japan.
Eribulin is a microtubule dynamics inhibitor, and earlier research had suggested it may be effective in NSCLC. The new trial was a randomized, open-label, phase III study including 540 patients who had received at least two prior therapies, including a platinum-based doublet and an EGFR tyrosine kinase inhibitor. They were randomized to receive either eribulin (270 patients) or TPC (270 patients). Results of the study were published in Annals of Oncology.
Source: Cancer Network